O-Demethylrotenone
O-Demethylrotenone is a rotenone (HY-B1756) derivative and a photodegradation product of rotenone that induces acute intraperitoneal toxicity. The acute intraperitoneal LD50 of O-Demethylrotenone in Mus musculus is 8.0 mg/kg.
For research use only. We do not sell to patients.
- CAS No.: 36375-21-0
- Formula: C22H20O6
- Molecular Weight:380.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
O-Demethylrotenone (1 g rotenone, equimolar boron tribromide, 12 mL dichloromethane; 2 min at -10 °C) is synthesized from rotenone via demethylation with boron tribromide, exhibits characteristic spectral and physical properties, and can be converted back to rotenone via methylation[1].
O-Demethylrotenone (1 g rotenone in 600 mL methanol; 2 hr ultraviolet irradiation with oxygen bubbling) is a neutral product of rotenone photodecomposition in oxygenated methanol solution under ultraviolet irradiation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:white mice (adult male)[1]
-
Dosage:8.0 mg/kg
-
Administration:i.p.; single dose
-
Result:Determined a 24-hour intraperitoneal LD50 of 8.0 mg/kg.
Chemical Information
-
CAS No. 36375-21-0
-
Molecular Weight 380.39
-
Formula C22H20O6
-
SMILES
O=C1[C@@]2([H])C3=CC(OC)=C(O)C=C3OC[C@@]2([H])OC4=C(C[C@@H](O5)C(C)=C)C5=CC=C41
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)